The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: Enthusiasm lost too soon?

CNS Neuroscience and Therapeutics

Volumn 16, Issue 6, 2010, Pages 362-373

  Sellner, Johann ^a   Weber, Martin S ^a   Vollmar, Patrick ^a   Mattle, Heinrich P ^b   Hemmer, Bernhard ^a   Stüve, Olaf ^c,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Immunomodulatory therapy; Interferon beta; Multiple sclerosis; Statin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; BETA1A INTERFERON; CCL1 CHEMOKINE; CXCL11 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLATIRAMER; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MEVINOLIN; MITOXANTRONE; MONOCYTE CHEMOTACTIC PROTEIN 3; NATALIZUMAB; SIMVASTATIN; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

BLOOD BRAIN BARRIER; BRONCHITIS; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE EXPRESSION; HUMAN; HYPERLIPIDEMIA; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; LEUKOCYTE MIGRATION; LEUKOCYTE MOTILITY; MULTIPLE SCLEROSIS; NEUROPROTECTION; PHAGOCYTOSIS; PROTEIN EXPRESSION; REVIEW; RHINITIS; SIDE EFFECT; SINUSITIS; TH17 CELL; TREATMENT INDICATION; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS;

EID: 78649232339     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00179.x     Document Type: Review

References (73)

1. McFarland HF, Martin R,. Multiple sclerosis: A complicated picture of autoimmunity. Nat Immunol 2007; 8: 913 - 919.
2. Kieseier BC, Wiendl H, Leussink VI, Stüve O,. Immunomodulatory treatment strategies in multiple sclerosis. J Neurol 2008; 255: 15 - 21.
3. Soos JM, Stüve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil SS,. Cutting edge: Oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J Immunol 2002; 169: 2231 - 2235.
4. Youssef S, Stuve O, Patarroyo JC, et al,. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78 - 84.
5. Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ,. Statins as immunomodulators: Comparison with interferon-beta 1b in MS. Neurology 2002; 59: 990 - 997.
6. Aktas O, Waiczies S, Smorodchenko A, et al,. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197: 725 - 733.
7. Sena A, Pedrosa R, Graca Morais M,. Therapeutic potential of lovastatin in multiple sclerosis. J Neurol 2003; 250: 754 - 755.
8. Vollmer T, Key L, Durkalski V, et al,. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607 - 1608. (Pubitemid 38625664)
9. Waubant E, Pelletier D, Mass M, et al,. Atorvastatin therapy in patients with clinically isolated syndrome and high-risk for conversion to multiple sclerosis: The STAyCIS study. Mult Scler 2009; 15: S272.
10. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT,. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008; 71: 1390 - 1395.
11. Sellner J, Greeve I, Findling O, et al,. Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis. Neurochem Int 2008; 53: 17 - 21.
12. Feng X, Han D, Kilaru B, TB N, Reder AT,. Inhibitory effect of high-dose atorvastatin on interferon-beta signalling in multiple sclerosis. Mult Scler 2009; 15: S78.
13. Dhawan N, Reder AT,. Statins block interferon signaling in human immune cells: Potential loss of the therapeutic effect of IFN beta in multiple sclerosis. Neurology 2007; 68: A364.
14. Paul F, Waiczies S, Wuerfel J, et al,. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 2008; 3: e1928.
15. Rudick RA, Pace A, Rani MR, et al,. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 2009; 72: 1989 - 1993.
16. Lanzillo R, Orefice G, Quarantelli M, et al,. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy. Mult Scler 2010; 16: 450 - 454.
17. Sörensen PS, Frederikson IL, Lycke J, Sellebjerg E,. Does simvastatin antagonise the effect of interferon beta? Interim safety analysis of the ongoing SIMCOMBIN study. Mult Scler 2007; 13: S25.
18. Markovic-Plese S, Speer D, Jin J, Chen J, Smrtka J, Ingram L, Jewells V,. Statin and intramuscular interferon beta-1a combination therapy is safe and well tolerated in patients with clinically isolated syndrome suggestive of multiple sclerosis: A pilot study. Mult Scler 2007; 13: S270.
19. Oztekin NS, Oztekin FM, Munis OB,. Atorvastatin combined with interferon beta 1a in relapsing-remitting multiple sclerosis: Preliminary results of a 24 month randomized open-label clinical trial. Mult Scler 2008; 14: S171.
20. Clark LT,. Treating dyslipidemia with statins: The risk-benefit profile. Am Heart J 2003; 145: 387 - 396.
21. Lutjohann D, Stroick M, Bertsch T, et al,. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids 2004; 69: 431 - 438.
22. Evans BA, Evans JE, Baker SP, et al,. Long-term statin therapy and CSF cholesterol levels: Implications for Alzheimer's disease. Dement Geriatr Cogn Disord 2009; 27: 519 - 524.
23. Saher G, Brugger B, Lappe-Siefke C, et al,. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 2005; 8: 468 - 475.
24. Weber MS, Youssef S, Dunn SE, et al,. Statins in the treatment of central nervous system autoimmune disease. J Neuroimmunol 2006; 178: 140 - 148.
25. Nath N, Giri S, Prasad R, Singh AK, Singh I,. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 2004; 172: 1273 - 1286.
26. Neuhaus O, Hartung HP,. Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Rev Neurother 2007; 7: 547 - 556.
27. Van Der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL,. Statins: Mechanisms of neuroprotection. Prog Neurobiol 2009; 88: 64 - 75.
28. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, Steinman L,. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006; 203: 401 - 412.
29. Ahn KS, Sethi G, Aggarwal BB,. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway. Biochem Pharmacol 2008; 75: 907 - 913.
30. Greenwood J, Steinman L, Zamvil SS,. Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6: 358 - 370.
31. Tsakiri A, Tsiantoulas D, Frederiksen J, Svane IM,. Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatin. Exp Neurol 2010; 221: 320 - 328.
32. Peng X, Jin J, Giri S, et al,. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J Neuroimmunol 2006; 178: 130 - 139.
33. Paintlia AS, Paintlia MK, Singh AK, Stanislaus R, Gilg AG, Barbosa E, Singh I,. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J Neurosci Res 2004; 77: 63 - 81.
34. Stanislaus R, Gilg AG, Singh AK, Singh I,. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by Lovastatin. Neurosci Lett 2002; 333: 167 - 170.
35. Waiczies S, Prozorovski T, Infante-Duarte C, Hahner A, Aktas O, Ullrich O, Zipp F,. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J Immunol 2005; 174: 5630 - 5635.
36. Stuve O, Youssef S, Weber MS, et al,. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Inves 2006; 116: 1037 - 1044.
37. Zhang X, Markovic-Plese S,. Statins' immunomodulatory potential against Th17 cell-mediated autoimmune response. Immunol Res 2008; 41: 165 - 174.
38. Miron VE, Zehntner SP, Kuhlmann T, et al,. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol 2009; 174: 1880 - 1890.
39. Klopfleisch S, Merkler D, Schmitz M, et al,. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci 2008; 28: 13609 - 13614.
40. Schulz JG, Bosel J, Stoeckel M, Megow D, Dirnagl U, Endres M,. HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem 2004; 89: 24 - 32.
41. Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I,. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. Faseb J 2005; 19: 1407 - 1421.
42. Paintlia AS, Paintlia MK, Singh AK, Singh I,. Inhibition of Rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol 2008; 73: 1381 - 1393.
43. Sellner J, Greeve I, Mattle HP,. Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. Mult Scler 2008; 14: 981 - 984.
44. Weitz-Schmidt G,. Lymphocyte function-associated antigen-1 blockade by statins: Molecular basis and biological relevance. Endothelium 2003; 10: 43 - 47.
45. Stanislaus R, Singh AK, Singh I,. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 2001; 66: 155 - 162.
46. Ifergan I, Wosik K, Cayrol R, et al,. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis. Ann Neurol 2006; 60: 45 - 55.
47. Stepien K, Tomaszewski M, Czuczwar SJ,. Neuroprotective properties of statins. Pharmacol Rep 2005; 57: 561 - 569.
48. Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S, Piser T,. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 2003; 23: 11104 - 11111.
49. Dolga AM, Granic I, Nijholt IM, Nyakas C, Van Der Zee EA, Luiten PG, Eisel UL,. Pretreatment with lovastatin prevents N-methyl-D-aspartate-induced neurodegeneration in the magnocellular nucleus basalis and behavioral dysfunction. J Alzheimers Dis 2009; 17: 327 - 336.
50. Chen J, Zhang ZG, Li Y, et al,. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003; 53: 743 - 751.
51. Lu D, Goussev A, Chen J, Pannu P, Li Y, Mahmood A, Chopp M,. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma 2004; 21: 21 - 32.
52. Lu D, Qu C, Goussev A, et al,. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma 2007; 24: 1132 - 1146.
53. Dolga AM, Nijholt IM, Ostroveanu A, Ten Bosch Q, Luiten PG, Eisel UL,. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis 2008; 13: 111 - 122.
54. Cerezo-Guisado MI, Garcia-Marin LJ, Lorenzo MJ, Bragado MJ,. Lovastatin inhibits the growth and survival pathway of phosphoinositide 3-kinase/protein kinase B in immortalized rat brain neuroblasts. J Neurochem 2005; 94: 1277 - 1287.
55. Polman CH, Reingold SC, Barkhof F, et al,. Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment. Neurology 2008; 70: 1134 - 1140.
56. Stuve O, Bennett JL, Hemmer B, et al,. Pharmacological treatment of early multiple sclerosis. Drugs 2008; 68: 73 - 83.
57. Goldman MD, Cohen JA,. Statins to treat multiple sclerosis: Friend or foe? Neurology 2008; 71: 1386 - 1387.
58. Durelli L, Conti L, Clerico M, et al,. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009; 65: 499 - 509.
59. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S,. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009; 183: 5418 - 5427.
60. Taniguchi T, Takaoka A,. A weak signal for strong responses: Interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2001; 2: 378 - 386.
61. Singh P, Kohr D, Kaps M, Blaes F,. Influence of statins on MHC class I expression. Ann N Y Acad Sci 2009; 1173: 746 - 751.
62. Zhang X, Jin J, Peng X, Ramgolam VS, Markovic-Plese S,. Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 2008; 180: 6988 - 6996.
63. Kagami S, Owada T, Kanari H, et al,. Protein geranylgeranylation regulates the balance between Th17 cells and Foxp3+ regulatory T cells. Int Immunol 2009; 21: 679 - 689.
64. Markovic-Plese S, Jewells V, Speer D,. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2009; 72:1965; author reply 1965 - 1966.
65. Kamm CP, Mattle HP,. SWiss Atorvastatin and interferon Beta-1b trial in multiple sclerosis (SWABIMS): Rationale, design and methodology. Trials 2009; 10: 115.
66. Sellner J, Greeve I, Leib SL, Mattle HP,. Atorvastatin does not alter interferon Beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis. Arch Neurol 2008; 65: 672 - 674.
67. Sellner J, Greeve I, Findling O, Grandgirard D, Leib SL, Mattle HP,. Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis. Clin Exp Immunol 2008; 152: 280 - 284.
68. Greeve I, Sellner J, Minten C, et al,. Effects of immunomodulatory treatment in multiple sclerosis on the transendothelial migration of T-cells across the blood-brain barrier. Mult Scler 2009; 15: S237.
69. Kieseier BC, Archelos JJ, Hartung HP,. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 2004; 61: 929 - 932.
70. Sellner J, Simon F, Meyding-Lamade U, Leib SL,. Herpes-simplex virus encephalitis is characterized by an early MMP-9 increase and collagen type IV degradation. Brain Res 2006; 1125: 155 - 162.
71. Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, Kowala M,. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol 2001; 1: 105 - 118.
72. Cepok S, Schreiber H, Hoffmann S, et al,. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol 2009; 66: 1216 - 1223.
73. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T,. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008; 14: 1091 - 1098.